Phase Ib pancreatic cancer data demonstrate Halozyme hyaluronan thesis

Progression-free survival (PFS) was twice as high and overall survival was three times as high for pancreatic cancer patients with high levels of tumor-associated hyaluronan (HA) who were treated with Halozyme Therapeutics's PEGPH20 (pegylated recombinant human hyaluronidase) plus gemcitabine than for patients whose tumors had low HA levels in a Phase Ib clinical trial.